The window for preventing Alzheimer's disease may open decades before memory loss begins, as brain circuits start malfunctioning in young adults carrying the APOE4 genetic variant. This discovery fundamentally shifts how we might approach early intervention for the 25% of people carrying this high-risk gene.
Using transgenic mice engineered to carry human APOE4, scientists demonstrated that hippocampal neurons become abnormally hyperactive long before traditional Alzheimer pathology emerges. These overactive circuits create an excitation-inhibition imbalance in the dentate gyrus, the brain's pattern separation hub critical for forming distinct memories. Single-nucleus RNA sequencing identified Nell2, a neural guidance protein, as a key driver of this early dysfunction. When researchers used CRISPR gene editing to reduce Nell2 expression, the abnormal brain activity normalized.
This research provides the first mechanistic explanation for why APOE4 carriers show subtle cognitive changes decades before clinical diagnosis. The findings suggest that targeting hyperexcitability rather than amyloid plaques could prove more effective for prevention. Current Alzheimer therapeutics focus on removing protein aggregates after extensive brain damage has occurred. Instead, identifying and treating circuit dysfunction in healthy APOE4 carriers during their 30s and 40s could prevent the cascade leading to neurodegeneration. The Nell2 pathway represents a concrete therapeutic target, though translating mouse findings to human interventions requires extensive validation. This work exemplifies precision medicine's potential—using genetic risk profiles to guide preventive treatments before irreversible damage occurs.